Organization
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3 abstracts
Abstract
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.Org: Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Gustave Roussy and Paris Saclay University, Faculty of Medicine, Villejuif / Kremlin-Bicêtre, France, Samsung Medical Center, Seoul, South Korea, Asan Medical Center, Seoul, South Korea,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.Org: University of Duisburg-Essen and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, Peter MacCallum Cancer Centre, Melbourne, Australia, UCLA Department of Nuclear Medicine, Los Angeles, CA, University of California Los Angeles, Los Angeles, CA,